Please note that masks must still be worn within NYOH practices regardless of vaccination status.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

Ph2 Selinexor + Pembro Newly Dx Melanoma

A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN RECURRENT ADVANCED MELANOMA (XPORT-MEL-033)

Disease Types: Melanoma,&nbs

Available at: {clinical_trial_location backspace="7"}Ph2 Selinexor + Pembro Newly Dx Melanoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}